Huvepharma is dedicated to advancing both human and animal health through innovative pharmaceutical solutions. The company emphasizes a comprehensive approach to production, mastering the entire cycle from strain development to product delivery. This in-house production capability allows Huvepharma to maintain high-quality standards and ensure the efficacy of its products, which include pharmaceuticals, feed additives, and vaccines. The company is also committed to sustainability, aiming to achieve energy self-sufficiency in its manufacturing facilities by 2030 and investing significantly in renewable energy sources. Their focus on sustainable livestock production integrates animal welfare, health, and environmental considerations, reflecting a holistic view of the challenges faced by the industry.

In addition to its product offerings, Huvepharma is actively engaged in research and development to enhance its capabilities and expand its portfolio. The company has invested in new R&D facilities and laboratories, doubled its fermentation capacity, and is constructing a new vaccine plant. This commitment to innovation is complemented by the introduction of digital tools like Aviapp®, which allows for the monitoring and analysis of poultry health and performance. Huvepharma's approach not only addresses current market needs but also anticipates future demands, positioning the company as a leader in the pharmaceutical industry while prioritizing effective disease management and alternative solutions to antibiotics.

Belgium

Huvepharma is a fast growing global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. The company also manufactures and markets enzymes for food, feed and industrial applications.
Huvepharma is a privately owned company headquartered in Sofia, Bulgaria.

Huvepharma

Company Details